Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132243 | 0.98 | TSHR (0.32) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| Bromide SCHEMBL22206792 | 0.96 | TSHR (0.32) | TSHRMAPK1HSD17B10TDP1THRB | |
| Fluoride SCHEMBL22206791 | 0.96 | TSHR (0.32) | TSHRMAPK1HSD17B10TDP1THRB | |
| Hydrochloric Acid SCHEMBL134284 | 0.96 | THRB (0.34) | TSHRMAPK1HSD17B10TDP1THRB | |
| Acetic Acid SCHEMBL2788321 | 0.93 | TSHR (0.33) | TSHRMAPK1HSD17B10TDP1THRB | |
| Cyanide SCHEMBL22191188 | 0.93 | TSHR (0.30) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL22206793 | 0.91 | PARP1 (0.30) | — | |
| SCHEMBL29082836 | 0.90 | — | — | |
| SCHEMBL29082823 | 0.88 | — | — | |
| SCHEMBL22190612 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010123963-A2 | UTILIZING ELECTROMAGNETIC RADIATION TO ACTIVATE FILTERCAKE BREAKERS DOWNHOLE | HORTON AMY C (US) | 2010-10-28 | — | — | WO | claimed |
| US-20100263867-A1 | UTILIZING ELECTROMAGNETIC RADIATION TO ACTIVATE FILTERCAKE BREAKERS DOWNHOLE | HORTON AMY C | 2010-10-21 | — | — | US | claimed |
| CN-116655528-A | Preparation method of 1-methyl nicotinoyl ammonium chloride | 宁波百思佳医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-10864207-B2 | Method of treating endothelial dysfunction | Celagenex Research (India) Pvt. Ltd. (IN) | 2020-12-15 | — | — | US | disclosed |
| US-20200222383-A1 | POTENT SYNERGISTIC COMPOSITIONS OF VASOACTIVE MEDIATORS ENHANCERS FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION | Celagenex Research (India) Pvt. Ltd. (IN) | 2020-07-16 | — | — | US | disclosed |
| WO-2010123963-A2 | UTILIZING ELECTROMAGNETIC RADIATION TO ACTIVATE FILTERCAKE BREAKERS DOWNHOLE | HORTON AMY C (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100263867-A1 | UTILIZING ELECTROMAGNETIC RADIATION TO ACTIVATE FILTERCAKE BREAKERS DOWNHOLE | HORTON AMY C | 2010-10-21 | — | — | US | disclosed |
| US-20030158237-A1 | Combination of antioxidant substances for the treatment of alzheimer's disease | COLBA R & D INC. (CA) | 2003-08-21 | — | — | US | disclosed |
| EP-1288238-A1 | Compositions of matter having bioactive properties | Schmitz, Robert A. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20030031715-A1 | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof | PURDUE RESEARCH FOUNDATION | 2003-02-13 | — | — | US | disclosed |
| WO-2002030466-A2 | PHARMACEUTICAL APPLICATIONS OF HYDROTROPIC AGENTS, POLYMERS THEREOF, AND HYDROGELS THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2002-04-18 | — | — | WO | disclosed |
| US-6299892-B1 | INCORPORATING INTO DELIVERY VEHICLES SUITABLE FOR EFFECTING DESIRED ANTIMICROBIAL USE, SOAPS AND DETERGENTS | SCHMITZ ROBERT A (US) | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10864207-B2 | Method of treating endothelial dysfunction | NNMT, NOS1, NOS2 | GABRR1 2557/4885TSHR 3138/4885MAPK1 606/4885 |
| US-20030031715-A1 | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof | HMGB2, HTT, ABCG2 | GABRR1 2875/4885TSHR 3523/4885MAPK1 2570/4885 |
| US-20200222383-A1 | POTENT SYNERGISTIC COMPOSITIONS OF VASOACTIVE MEDIATORS ENHANCERS FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION | NNMT, NOS1, NOS2 | GABRR1 2660/4885TSHR 2998/4885MAPK1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.